Old Web
English
Sign In
Acemap
>
authorDetail
>
Youyi Shu
Youyi Shu
Janssen Pharmaceutica
Oncology
Pathology
Prostate cancer
Apalutamide
Medicine
3
Papers
20
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).
2019
Journal of Clinical Oncology
Eric J. Small
Fred Saad
Simon Chowdhury
S. Oudard
Boris Hadaschik
Julie N. Graff
David Olmos
Paul Mainwaring
Ji Youl Lee
Hiroji Uemura
Angela Lopez-Gitlitz
Byron M. Espina
Youyi Shu
Wayne R. Rackoff
Oliver Brendan Rooney
Anil Londhe
Shinta Cheng
Matthew R. Smith
Show All
Source
Cite
Save
Citations (7)
SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
2018
Journal of Clinical Oncology
Eric J. Small
Fred Saad
Simon Chowdhury
Boris Hadaschik
Julie N. Graff
David Olmos
Paul N. Mainwaring
Hiroji Uemura
Angela Lopez-Gitlitz
Géralyn C. Trudel
Byron M. Espina
Youyi Shu
Youn C. Park
Wayne R. Rackoff
Margaret K. Yu
Matthew R. Smith
Show All
Source
Cite
Save
Citations (10)
Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): An analysis from the phase 3 SPARTAN trial.
2018
Journal of Clinical Oncology
Eric J. Small
Fred Saad
Dana E. Rathkopf
Boris Hadaschik
Simon Chowdhury
Margaret K. Yu
Angela Lopez-Gitlitz
Oliver Brendan Rooney
Youyi Shu
Mohamed Darif
Matthew R. Smith
Show All
Source
Cite
Save
Citations (3)
1